We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly to Acquire POINT Biopharma for $1.4B to Expand Oncology Capabilities
Lilly to Acquire POINT Biopharma for $1.4B to Expand Oncology Capabilities
Eli Lilly and Point Biopharma Global have announced that Lilly will pay $1.4 billion to acquire Point, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.